Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries
DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI)...
Clinical Trial
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital
-- Brooks Rehabilitation Hospital adds a second site to the registrational program in stroke, and brings the total number of...
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality...
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Correction: The initial release stated Mr. Peter Croden was previously Global President of Upjohn/Pfizer Animal Health Division in Germany. The...
Parexel and Japanese Foundation for Cancer Research Announce Strategic Alliance
Collaboration streamlines patient access to oncology clinical trials; further expands Parexel's Site Alliance Network across Asia/PacificDURHAM, N.C. and TOKYO, Jan. 10,...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
WESTON, Fla., Jan. 10, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced...
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old...
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
Leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial...
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Cantargia Reports Phase I Clinical Progress in the CAN10 Project
LUND, SWEDEN / ACCESSWIRE / January 9, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported encouraging progress...
Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to...
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the...
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Athena will employ its successful history of securing government contracts, spearheading such initiativesJACKSON CENTER, PA / ACCESSWIRE / January 9,...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions...
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive...
Branded Legacy, INC Successfully Closes Acquisition of All In Extracts, LLC
In a Move That Showcases the Power of Cooperation Over Competition, Companies Join Forces to Bring Exciting New Products to...
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and...